Introduction
Neurodegenerative disease is a term applied to a variety of conditions arising from a chronic breakdown and deterioration of the neurons, particularly those of the central nervous system. Alzheimer's disease (AD) was first described in 1906 by a Bavarian neuropsychiatrist Alois Alzheimer [1] . It is a complex, multifactorial, progressive, neurodegenerative disease primarily affecting the elderly population and is estimated to account for 50-60% of dementia cases in persons over 65 years of age [2] . The pathophysiology of AD is complex and involves several different biochemical pathways. The first neurotransmitter defect discovered in AD involved acetylcholine (ACh), which plays an important role in memory and learning. However, in patients with AD, the ACh which is released has a very short half-life due to the presence of large amounts of the enzymes: acetyl cholinesterase (AChE) and butyrylcholinesterase (BChE), which are both present in the brain and are detected among neurofibrillary tangles and neuritic plaques [3] . These enzymes hydrolyse the ester bond in the ACh molecule, leading to loss of stimulatory activity. Hodges [4] demonstrated that the inhibition of AChE holds a key role not only to enhance cholinergic transmission in the brain but also to reduce the aggregation of -amyloid and the formation of the neurotoxic fibrils in AD. Therefore, AChE and BChE inhibitors have become remarkable alternatives in treatment of AD [5] . Existing anticholinesterase drugs (for example, tacrine, donepezil, physostigmine, galanthamine, and heptylphysostigmine) for the treatment of dementia are reported to have several dangerous adverse effects such as hepatotoxicity, short duration of biological action, low bioavailability, adverse cholinergic side effects in the periphery, and a narrow therapeutic window [6] . This necessitates the interest in finding better AChE inhibitors from natural resources.
The neurotransmitter ACh is synthesised in presynaptic cholinergic neurons by choline acetyltransferase (CAT or ChAT). The process entails transfer of an acetyl group from acetyl-coenzyme A to choline. The choline released in the process is reused in synthesizing new ACh. Inhibition of AChE increases the amount of ACh available for neurotransmission. Choline is the precursor of phosphatidylcholine (PC), a main component of Leishmania promastigote membranes [7] . Therefore, inhibition of choline formation may decrease Leishmania survival. This hypothesis can be tested by using inhibitors of the acetylcholinesterase enzyme (AChE), which catalyzes the hydrolysis of acetylcholine to choline and acetic acid, as leishmanicidal compounds. This may identify another mechanism of action for antileishmanial activity [8] .
Leishmaniasis is still one of the most neglected diseases in the world. During the last 10 years, many scientific studies involving this disease have been related to treatment strategies and led to a reduction in drug prices; however, the morbidity and mortality of this disease has continued to increase worldwide [9] . For more than 50 years, the traditional chemotherapy used to treat leishmaniasis has been based on the use of pentavalent antimonial drugs. However, the toxicity of these agents and their side effects, along with the development of resistance and differences in strain sensitivity, are challenges that must be overcome [10] .
Canarium patentinervium Miq. is a rare plant from the family Burseraceae and genus Canarium found in the Asia Pacific region previously recorded for its usage in wound healing by the indigenous people of Malaysia. In continuation to our earlier studies on the pharmacological properties of Canarium patentinervium Miq. [11, 12] , this study investigates the antiacetylcholinesterase and antileishmanial activities of the plant. To the best of our knowledge, this is the first comprehensive study on isolated compounds from Canarium patentinervium Miq. investigating the antiacetylcholinesterase and antileishmanial activities. 
Materials and Method

Extraction and Isolation.
Dried and grinded sample of leaves (2.8 kg) was soaked in hexane with the ratio of 1 : 3 parts of sample to solvent for 2 h in a 60 ∘ C water bath then filtered and concentrated with a rotary evaporator (Buchi, R-200 Switzerland). This was repeated 3 times. Thereafter the leaves and barks were left to air dry completely for 3 days before repeating the whole process with chloroform and then ethanol, respectively. The yield for the hexane, chloroform, and ethanol extract of leaves was 1.25%, 1.11%, and 6.45%, respectively. The ethanol extract of the leaves (80 g) was then partitioned with petroleum ether, chloroform, and water to yield the respective solvent extracts. The chloroform extract (5 g) was further purified by silica gel chromatography (4 cm × 90 cm, 0.063-0.200 mesh) and eluted with a chloroform/methanol gradient elution (the ratio from 100 : 0 to 8 : 100). Thirteen column fractions were collected and analysed by TLC (chloroform/methanol). Fractions with similar TLC pattern were combined to total of four fractions. Fraction B that was yielded from chloroform/methanol ratio 100 : 4 was rechromatographed on a preparative TLC (2 mm thickness) with solvent system chloroform/methanol (ratio of 1000 : 15) yielding total 7 bands. Band three was collected and rechromatographed on preparative TLC (0.5 mm thickness) with solvent system chloroform/methanol (ratio of 89 : 11) to yield four bands, with band two yielding compound 1 (49 mg) and band three yielding compound 2 (11 mg) ( Figure 1 ). The water extract (24 g) was further purified by Sephadex LH-20 with mobile phase ethanol yielding 16 fractions which was then recombined to four fractions. Fraction B was loaded on Sephadex LH-20 with mobile phase methanol yielding 3 fractions, whereby fraction B was compound 3 (14 mg). Crude chloroform extract (7.2 g) was dissolved in dichloromethane : methanol (2 : 1) and subjected to PTLC with mobile phase ethyl acetate : methanol (10 : 1) yielding 3 bands. Bands 1 and 2 were run on semipreparative HPLC with mobile phase ethyl acetate : acetonitrile (6 : 1) which yielded compound 4 (15 mg) at retention time (Rt) = 14.1 min and compound 5 (3.4 mg) at Rt = 15.8. Band 3 was partitioned between water and ethyl acetate and the aqueous layer was run on semipreparative HPLC with mobile phase ammonium bicarbonate : acetonitrile. Compound 6 (3.0 mg) was eluted at Rt = 3.3 min.
Antiacetylcholinesterase Assay.
Acetylcholinesterase (AChE) inhibitory activity was measured by slightly modifying the spectrophotometric method developed by Ellman et al. [13] . 5,5 -Dithio-bis(2-nitrobenzoic) acid (DTNB) was used for the measurement of anti-AChE activity. All the other reagents and conditions were the same as described previously [10] . Test sample and galanthamine which were used as positive control were dissolved in dimethyl sulfoxide (DMSO, R and M) prior to assay at a stock concentration of 5 mM, and serial dilution was done accordingly to obtain a good EC 50 curve. In brief, 130 L of 0.1 mM sodium phosphate buffer (pH 8.0), 20 L of DTNB, 20 L of test solution, and 20 L of AChE solution were added by multichannel automatic pipette (Eppendorf, Germany) in a 96-well microplate and incubated for 15 min at 25 ∘ C. The reaction was then initiated with the addition of 10 L of acetylthiocholine iodide. The hydrolysis of acetylthiocholine iodide was monitored by the formation of the yellow 5-thio-2-nitrobenzoate anion as a result of the reaction of DTNB with thiocholines, catalysed by enzymes at a wavelength of 412 nm utilizing a 96-well microplate Thermo Scientific Varioskan Flash microtiter plate reader, and linked to a computer equipped with SkanIt Software 2.4.3. Percentage inhibition of AChE was determined by comparison of rates of reaction of samples relative to blank sample (ethanol in phosphate buffer pH = 8) using the formula ( − )/ × 100, where is the activity of enzyme without test sample and is the activity of enzyme with test sample. The experiments were done in triplicate. Galanthamine was used as reference.
Antileishmanial Assay.
The study on the antileshmanial activity of the extracts and isolated compounds was performed according to the standard methods as described by Mosmann [14] against Leishmania donovani (strain MHOM/IN/1983/AG83) promastigotes by using MTT colorimetric assay. Amphotericin B was used as the positive control in all the experiments. Promastigotes (5 × 10 5 cells/mL; 300 L) were treated with and without tested samples at concentrations of 100 and 500 g/mL and incubated at 22 ± 
Statistical Analysis.
Concentration-response curves were calculated using the Prism software package 5.00 for Windows, GraphPad Software, San Diego, CA, USA, http://www .graphpad.com/ (GraphPad, San Diego, USA) and data were reported as mean and SD values obtained from a minimum of three determinations. Nonlinear best fit was plotted with SD and 95% confidence interval. All data were expressed as mean ± standard deviation. Data were analysed using oneway Anova followed by Tukey test using GraphPad Prism5 software. A significant difference was considered at the level of < 0.01. H-8, s, 1H 
Results and Discussions
The Antiacetylcholinesterase Activity.
In the antiacetylcholinesterase assay, chloroform extract of the barks displayed the best activity (IC 50 = 88.59 ± 0.14 g/mL) as opposed to galanthamine (IC 50 = 0.74 ± 0.06 g/mL). The BioMed Research International ethanol extract of barks and leaves follows through with IC 50 = 186.00 ± 0.15 g/mL and IC 50 = 201.24 ± 0.15 g/mL, resp. Hexane extracts of bark and leaves and the chloroform extract of leaves had the lowest enzyme inhibition activity (IC 50 = 570.00 ± 0.08 g/mL, IC 50 = 842.00 ± 0.25 g/mL, and IC 50 = 1780.00 ± 0.24 g/mL, resp.). Thus, the potency of activity against AChE was chloroform extract of barks > ethanol extract of barks > ethanol extract of leaves > hexane extract of barks > hexane extract of leaves > chloroform extract of leaves ( Table 1 ). The antiacetylcholinesterase values for isolated compounds are shown in Table 1 and Figure 2 . Only 4 compounds showed moderate enzyme inhibition, namely, syringic acid (IC 50 = 29.53 ± 0.19 g/mL), scopoletin (IC 50 = 51.00 ± 0.02 g/mL), scoparone (IC 50 = 86.58 ± 0.05 g/mL), and vomifoliol (IC 50 = 96.64 ± 0.09 g/mL) as shown in Figure 2 . Flavonoid (+)-catechin showed poor enzyme inhibition with IC 50 values > 100 g/mL. This assay measures the inhibition activity against AChE, which is the key enzyme in the hydrolysis of acetylcholine that is responsible for muscle and organ relaxations. Acetyl cholinesterase inhibitors are therefore used medicinally to treat myasthenia gravis to increase neuromuscular transmission and to treat Alzheimer's disease (deficiency in the production of acetylcholine). Furthermore, oxidative and inflammatory processes are among the pathological features associated with the central nervous system in Alzheimer's disease [24] . The brain of patients suffering from AD is said to be under oxidative stress as a result of perturbed ionic calcium balances within their neurons and mitochondria [25] . Accumulating evidence suggests that oxidative damage to neurons plays an important role in the AD pathogenesis [26] . Because of the unclear pathogenesis of AD, there have been several hypothesis associated with the disease such as amyloid-peptide-containing plaque formation, excess metal ions, oxidative stress, and reduced acetylcholine levels. Thus, efforts to reduce oxidative injury may prove beneficial in retarding or preventing the onset and progression of AD in patients. In previous studies [11] , chloroform extract of barks had displayed good antioxidant potential via nonenzymatic assays. In addition, the anti-acetylcholinesterase activity exhibited in this study (IC 50 = 88.59 ± 0.14 g/mL) suggest that the chloroform extract of the barks hold lead compounds that inhibit acetylcholinesterase activity as well as reduce the oxidative stress with possible neuroprotective effects. This was somewhat evident with the isolation of syringic acid that had the lowest AChE inhibition among the isolated compounds (IC 50 = 29.53 ± 0.19 g/mL). Up to date, quite a lot of studies have reported affirmative effects of phenolics in neurodegenerative diseases depending upon their antioxidative properties [27] . However, there has been a small number of data on AChE inhibitory activities of phenolic compounds. Among the phenolics isolated in this study only syringic acid, a phenolic acid, exhibited good AChE inhibition (IC 50 = 29.53 ± 0.19 g/mL), lowest of all compounds tested. The literature concerning the role of phenolic acids and their derivatives in the neuroprotection of the CNS is, however, still incomplete. Thus the actual mechanism of inhibition needs to be investigated.
Only scopoletin, scoparone, vomifoliol, and syringic acid showed AChE inhibition at IC 50 < 100 g/mL. Studies have also shown that naturally occurring as well as the chemically synthesised coumarin analogs exhibit potent AChE inhibitory activity [28] . Coumarin ring seems to be essential for the optimal activity and its replacement with related structural moiety such as chromone is associated with loss of AChE inhibitory activity. The substituents at coumarin moiety particularly at 6th and 7th positions also influence the activity in a significant manner. The presence of electrondonating groups such as -OCH 3 , -OH, and -NH 2 increase the activity and it has been generally attributed to an increase in lipophilicity of compounds [29] . This might explain good activity of scopoletin (IC 50 = 51.00 ± 0.02 g/mL) and scoparone (IC 50 = 86.58 ± 0.05 g/mL) as both have electron donating groups at 6th and 7th positions. The presence of bulkier substituents at 6th and 7th positions of the coumarin is associated with significant loss in AChE inhibitory activity indicating the critical role of electronic as well as steric effects in influencing the AChE inhibitory activity [29] ; this explains why scoparone has higher IC 50 due to it having two bulkier methoxy groups. Cyclohexenone derivatives, vomifoliol had moderate AChE inhibition (IC 50 = 96.64±0.09 g/mL), which is to the best of our knowledge the first to be reported.
The Antileishmanial Activity.
The result of the in vitro effect of extracts on Leishmania donovani is summarized in oils present in the hexane extracts as shown previously in the family of Burseraceae [30] .
Scopoletin exhibited moderate antileishmanial activity (IC 50 = 163.30 ± 0.32 g/mL) followed by lioxin, vomifoliol, scoparone, and (+)-catechin. Comparing the anti-AChE and antiparasitic activity, it can be deduced that scopoletin, scoparone, and (+)-catechin seemed to show correlation in both activities. Inhibitors of acetylcholinesterase (AChE) may decrease Leishmania survival by inhibiting choline formation from acetylcholine through hydrolysis. Again, the lactone groups present in the coumarins, namely, scopoletin and scoparone, are also present in the structures of Annonaceous acetogenins that showed leishmanicidal activity [10] . This might explain why scopoletin and scoparone showed correlation in both the assays. In fact, the AChE inhibitory activity of a previous study on scoparone indicated a possible mechanism of action by disrupting leishmania cell membranes [8] . There has been a hypothesis on the mechanism of action of coumarins acting on the same pathway as above compounds, resulting in net negative effects on choline uptake by the parasite [8] . Nevertheless, the antileishmanial activity of (+)-catechin may be related to its ability to chelate iron (Fe), depriving this essential nutrient from the intracellular forms [31] . However, lioxin and vomifoliol had lower anti-AChE activity but showed higher antileishmanial activity. Vomifoliol and lioxin both may be exhibiting their antileishmanial activity by mechanisms other than choline inhibition such as interference with the purine transporter as Leishmania species are unable to synthesize purines de novo and thus salvage these from their host. A graphical abstract of this study is shown in Figure 3. 
Conclusion
This study is an important endeavour for the discovery of potent biologically active molecules for the treatment of neurodegenerative and parasitic diseases. Since only 12% of the 75 species of Canarium have been studied for their pharmacological activities, this study promises an unopened crypt of various secondary metabolites as lead compounds and various biological effects that needs to be uncovered and investigated. As modern cultures and scientific advances spread around the world, the depth of the knowledge store of traditional use still remains crucial. The full significance of the indigenous knowledge forfeited may not be realised. It is thus important that the knowledge be documented and the traditional use be given some credence through modern scientific studies. Canarium patentinervium Miq. is such an example.
